Histone Deacetylase 9 Activates IKK to Regulate Atherosclerotic Plaque Vulnerability

@article{Asare2020HistoneD9,
  title={Histone Deacetylase 9 Activates IKK to Regulate Atherosclerotic Plaque Vulnerability},
  author={Yaw Asare and Thomas A. Campbell-James and Yury Bokov and Lydia Luya Yu and Matthias Prestel and Omar El Bounkari and Stefan Roth and Remco T. A. Megens and Tobias Straub and Kyra Thomas and Guangyao Yan and Melanie Schneider and Natalie Ziesch and Steffen Tiedt and Carlos Silvestre-Roig and Quinte Braster and Yishu Huang and Manuela Schneider and Rainer Malik and Christof Haffner and Arthur Liesz and Oliver Soehnlein and J{\"u}rgen Bernhagen and Martin Dichgans},
  journal={Circulation Research},
  year={2020},
  volume={127},
  pages={811 - 823}
}
Supplemental Digital Content is available in the text. Rationale: Arterial inflammation manifested as atherosclerosis is the leading cause of mortality worldwide. Genome-wide association studies have identified a prominent role of HDAC (histone deacetylase)-9 in atherosclerosis and its clinical complications including stroke and myocardial infarction. Objective: To determine the mechanisms linking HDAC9 to these vascular pathologies and explore its therapeutic potential for atheroprotection… 

Figures from this paper

New Insight in HDACs: Potential Therapeutic Targets for the Treatment of Atherosclerosis
TLDR
The members of HDACs in vascular systems are discussed, the diverse roles in AS are determined, the effects ofHDAC inhibitors on AS progression are revealed, and new insights are provided into the potential of HDac inhibitors as drugs for AS treatment.
The Histone Deacetylase 9 Stroke-Risk Variant Promotes Apoptosis and Inflammation in a Human iPSC-Derived Smooth Muscle Cells Model
TLDR
By demonstrating the relevance of the model and the efficacy of HDAC inhibitors, the model provides a robust phenotypic screening platform, which could be applied to other stroke-associated genetic variants.
HDAC9 exacerbates myocardial infarction via inactivating Nrf2 pathways.
TLDR
Taken together,HDAC9 knockout induced the activation of Nrf2 and protected heart from MI injury and the HDAC9/Nrf2 axis can be a novel marker for the treatment of MI.
Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review
TLDR
An updated view on the roles of HDACs (Class I, Class II, Class IV) and HDAC inhibitors in vascular dysfunction and AS is presented and the novel therapeutic targets and agents in atherosclerotic cardiovascular diseases are elaborate.
Diverse Epigenetic Regulations of Macrophages in Atherosclerosis
TLDR
The current understanding of the epigenetic machinery involving macrophage polarization is described to shed light on chronic inflammation-driving onset and progression of inflammaging-associated diseases, using AS as a prototypic example and the challenge for developing effective therapies targeting the methylation or histone modifications against these diseases is discussed.
Targeting epigenetics as atherosclerosis treatment: an updated view
TLDR
It is proposed that there is future window for targeting repressive histone modifications in atherosclerosis and there is sufficient potential for future clinical usage based on the outcomes in specific subgroups and the fact that the study was slightly underpowered.
HDAC9 Silencing Exerts Neuroprotection Against Ischemic Brain Injury via miR-20a-Dependent Downregulation of NeuroD1
TLDR
Overall, this study revealed that HDAC9 silencing could retard ischemic brain injury through the miR-20a/Neurod1 signaling, and was highly-expressed in MCAO mice and OGD-stimulated cells.
HDAC9: An Inflammatory Link in Atherosclerosis.
TLDR
It is clear that inflammation is a critical player in the pathogenesis of atherosclerosis and its complications, including stroke and myocardial infarction, and there is still an unmet need for additional therapies.
Targeting non-coding RNAs in unstable atherosclerotic plaques: Mechanism, regulation, possibilities, and limitations
TLDR
The regulatory mechanisms involved in the susceptibility of atherosclerotic plaque rupture are reviewed, the limitations of current approaches to treat plaque instability are discussed, and the potential clinical value of ncRNAs as novel diagnostic biomarkers and potential therapeutic strategies to improve plaque stability and reduce the risk of major cardiovascular events are highlighted.
...
1
2
3
...

References

SHOWING 1-10 OF 62 REFERENCES
Histone Deacetylase 9 Represses Cholesterol Efflux and Alternatively Activated Macrophages in Atherosclerosis Development
TLDR
It is concluded that macrophage HDAC9 upregulation is atherogenic via suppression of cholesterol efflux and generation of alternatively activated macrophages in atherosclerosis.
Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions
TLDR
It is shown that targeting the macrophage epigenome can improve atherosclerosis outcome and Hdac3 is identified as a potential novel therapeutic target in cardiovascular disease.
Histone Deacetylase 3 Is Critical in Endothelial Survival and Atherosclerosis Development in Response to Disturbed Flow
TLDR
It is demonstrated thatHDAC3 serves as an essential prosurvival molecule with a critical role in maintaining the endothelial integrity via Akt activation and that severe atherosclerosis and vessel rupture in isografted vessels of apolipoprotein E–knockout mice occur when HDAC3 is knocked down.
Inhibiting epigenetic enzymes to improve atherogenic macrophage functions.
Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death
TLDR
This work demonstrates that extracellular histone H4-mediated membrane lysis of smooth muscle cells (SMCs) triggers arterial tissue damage and inflammation, and identifies a form of cell death found at the core of chronic vascular disease that is instigated by leukocytes and can be targeted therapeutically.
An HDAC9-MALAT1-BRG1 complex mediates smooth muscle dysfunction in thoracic aortic aneurysm
TLDR
It is shown that the formation of a HDAC9-MALAT1-BRG1 complex promotes VSMC dysfunction in TAA by epigenetically altering the expression of key components of the cytoskeleton in VSMCs.
Histone Deacetylase Inhibitor Reduces Monocyte Adhesion to Endothelium Through the Suppression of Vascular Cell Adhesion Molecule-1 Expression
TLDR
TNF-&agr; activates ECs via multiple signaling pathways, and these pathways may be selectively targeted to modulate EC function, suggesting that TSA might be useful for the attenuation of the inflammatory response in EC.
Histone Deacetylase 9 Promotes Angiogenesis by Targeting the Antiangiogenic MicroRNA-17–92 Cluster in Endothelial Cells
TLDR
It is found that HDAC9 promotes angiogenesis and transcriptionally represses the microRNA (miR)-17–92 cluster, which is known for its antiangiogenic activity.
Inhibition of atherogenesis by the COP9 signalosome subunit 5 in vivo
TLDR
It is concluded that MLN4924 may be useful in preventing early atherogenesis, whereas selectively promoting CSN5-mediated deNEDDylation may be beneficial in all stages of atherosclerosis.
...
1
2
3
4
5
...